Combined Treatment for Mixed Incontinence

Phase 3

Completed

• Conditions: Urinary Incontinence, Urge; Urinary Incontinence, Stress
• Interventions: Procedure: Miduretheral Sling; Other: Miduretheral Sling with behavioral/pelvic floor therapy

• Registration Number: NCT01959347
• Lead Sponsor: NICHD Pelvic Floor Disorders Network

Brief Summary

The overarching goal of this randomized trial is to estimate the effect of combined midurethral sling (MUS) and peri-operative behavioral/pelvic floor therapy (BPTx) compared to MUS alone on successful treatment of MUI symptoms in 472 women. Secondary objectives include estimating the effect of combined treatment compared to MUS on improving overactive bladder (OAB) and stress urinary incontinence (SUI) outcomes separately, need for additional treatment, time to failure and identifying predictors of poor outcomes in this MUI population.

A supplemental study, The Human Microbiome Study of ESTEEM, will evaluate the urinary and vaginal microbiome as it relates to women with MUI, their treatment and unaffected controls.

Detailed Description

ESTEEM is a multi-center randomized trial of 472 women with MUI who have elected to undergo surgical treatment for SUI. Participants will be randomized to a peri-operative BPTx program+MUS versus MUS alone. The purpose is to compare combined MUS+BPTx versus MUS alone (control) on improving MUI symptoms at 1 year.

Patients will be assigned to one of the two treatment groups. Randomization will be stratified by clinical site and by UUI "severity," which will be defined by the number of urgency urinary IEs on diary.

The primary outcome for this study is the mean change from baseline in UDI-total score at 1 year postoperative. The UDI is a validated, disease-specific, patient-reported outcome (PRO) measure.

Secondary outcomes UUI/OAB outcomes will be measured using the UDI-irritative subscale that measures symptom burden, impact, and changes related to OAB. It is highly responsive to treatment-related change and is able to discriminate among levels of change in all bladder diary variables (urinary urgency, frequency and urge incontinence) and patient ratings of treatment benefit that will characterize how MUS may affect all OAB symptoms individually and as a whole. SUI symptom outcomes will be measured using the UDI-stress subscale to compare SUI outcomes between women randomized to MUS + BPTx versus MUS alone.

Other UUI/OAB outcomes that will be compared between groups include 1) the change in IE frequency and type, number of urgency episodes, urgency severity with voids, number of diurnal voids, and number of nocturnal voids using a bladder diary; 2) patient satisfaction with treatment using the OAB-SAT-q; 3) bother and heal related quality of life using the OAB-q subscale

For analyzing time to failure, "failure" will be defined as initiation of any additional treatment for either SUI or UUI/OAB symptoms during the follow-up period. Subjects lost to follow up will be censored at the time of their last visit.

Quality of life/global impression will be assessed be compared between treatment groups using the a) Incontinence Impact Questionnaire (IIQ), Pelvic Organ Prolapse/Urinary Incontinence Sexual Questionnaire (PISQ), c) European Quality of Life-5 Dimensions (EQ-5D), d) Adaptation Index and e) Patient Global Impression of Improvement (PGI-I) and Patient Global Impression of Severity (PGI-S).

Safety/additional treatments will be characterized as a) additional re-treatments for SUI or UUI within 12 months of treatment, and type of re-treatment and b) return to OR for sling revision due to worsened OAB symptoms.

To evaluate the association between PFM strength and improvements in UI symptoms, we will objectively assess PFM strength changes using the Peritron Perineometer, and instrument specifically designed for pelvic floor assessment.

Study Timeline

• Study First Submitted: 2013-10-08
• Study First Submitted QC: 2013-10-08
• Study First Posted: 2013-10-10
• Study Start: 2013-10-28
• Primary Completion: 2017-08-09
• Study Completion: 2017-09-29
• Results First Submitted: 2020-04-15
• Status Verified: 2020-05
• Results First Submitted QC: 2020-05-01
• Last Update Submitted: 2020-05-01
• Results First Posted: 2020-05-14
• Last Update Posted: 2020-05-14

Recruitment & Eligibility

• Status: COMPLETED
• Sex: Female
• Target Recruitment: 480

Inclusion Criteria

1. Presence of both SUI and UUI on bladder diary; and > 2 IEs/3 days

   1. > 1 Stress IE/3 day diary
   2. > 1 Urge IE/3 day diary

2. Reporting at least "moderate bother" from UUI item on the UDI "Do you usually experience urine leakage associated with a feeling of urgency, that is a strong sensation of needing to go to the bathroom?"

3. Reporting at least "moderate bother" from SUI item on UDI "Do you usually experience urine leakage related to coughing, sneezing, or laughing"

4. Diagnosis of SUI defined by a positive cough stress test (CST) or urodynamic evaluation within the past 18 months

5. Desires surgical treatment for SUI symptoms

6. Urinary symptoms >3 months

7. Subjects understand that BPTx is a treatment option for MUI outside of ESTEEM study protocol

8. Urodynamics within past 18 months

Exclusion Criteria

1. Anterior or apical compartment prolapse at or beyond the hymen (>0 on POPQ), regardless if patient is symptomatic

   a)Women with anterior or apical prolapse above the hymen (<0) who do not report vaginal bulge symptoms will be eligible

2. Planned concomitant surgery for anterior vaginal wall or apical prolapse > 0

   a)Women undergoing only rectocele repair are eligible

3. Women undergoing hysterectomy for any indication will be excluded

4. Active pelvic organ malignancy

5. Age <21 years

6. Pregnant or plans for future pregnancy in next 12 months, or within 12 months post-partum

7. Post-void residual >150 cc on 2 occasions, or current catheter use

8. Participation in other trial that may influence results of this study

9. Unevaluated hematuria

10. Prior sling, synthetic mesh for prolapse, implanted nerve stimulator for incontinence

11. Spinal cord injury or advanced/severe neurologic conditions including Multiple Sclerosis, Parkinsons

12. Women on anti-muscarinic therapy will be eligible after 3 week wash-out period

13. Non-ambulatory

14. History of serious adverse reaction to synthetic mesh

15. Not able to complete study assessments per clinician judgment, or not available for 12 month follow-up

16. Women who only report "other IE" on bladder diary, and do not report at minimum 1 stress and 1 urge IE/3 days

17. Diagnosis of and/or history of bladder pain or chronic pelvic pain

18. Women who had intravesical Botox injection within the past 12 months

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Miduretheral Sling (Control)	Miduretheral Sling	Miduretheral Sling (Control)
MUS+BPTx	Miduretheral Sling with behavioral/pelvic floor therapy	Miduretheral Sling with behavioral/pelvic floor therapy

Primary Outcome Measures

Name	Time	Method
Change From Baseline UDI Total Score	3, 6, and 12 Months	The Urogenital Distress Inventory (UDI) is a standardized a measure of overactive bladder symptoms and health-related quality of life. The UDI scale has a range from 0 to 300 with higher scores indicating greater distress. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline UDI Irritative Score	3, 6, and 12 Months	The Urogenital Distress Inventory is a standardized a measure of overactive bladder symptoms and health-related quality of life. The UDI Irritative subscale has a range from 0 to 100 with higher scores indicating greater distress. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.
Change From Baseline UDI Stress Score	3, 6, and 12 Months	The Urogenital Distress Inventory is a standardized a measure of overactive bladder symptoms and health-related quality of life. The UDI Stress subscale has a range from 0 to 100 with higher scores indicating greater distress. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.
Change From Baseline UDI Obstructive Score	3, 6, and 12 Months	The Urogenital Distress Inventory is a standardized a measure of overactive bladder symptoms and health-related quality of life. The UDI Obstructive subscale has a range from 0 to 100 with higher scores indicating greater distress. The change from baseline outcome is calculated as the difference in score at 3, 6, or 12 months and the score at baseline.

Trial Locations

Locations (10)

University of Alabama at Birmingham, Department of Obstetrics and Gynecology; 🇺🇸 Birmingham, Alabama, United States

Kaiser Permanente -- Downey; 🇺🇸 Downey, California, United States

Kaiser Permanente -- San Diego; 🇺🇸 San Diego, California, United States

University of New Mexico Health Sciences Center, Department of Obstetrics and Gynecology; 🇺🇸 Albuquerque, New Mexico, United States

Duke University, Duke Division of Urogynecology and Reconstructive Pelvic Surgery; 🇺🇸 Durham, North Carolina, United States

Cleveland Clinic, Department OB/GYN; 🇺🇸 Cleveland, Ohio, United States

University of Pennsylvania; 🇺🇸 Philadelphia, Pennsylvania, United States

Magee-Womens Hospital, Department of Obstetrics and Gynecology; 🇺🇸 Pittsburgh, Pennsylvania, United States

Brown/ Women and Infants Hospital of Rhode Island, Center for Women's Pelvic Medicine and Reconstructive Surgery; 🇺🇸 Providence, Rhode Island, United States

University of California at San Diego, UCSD Women's Pelvic Medicine Center; 🇺🇸 La Jolla, California, United States